CONMED Corporation Beats Q1 Estimates and Raises Revenue Guidance, Shares Steady
CONMED Corporation (NYSE:CNMD) reported its first-quarter 2026 financial results after the market close on Tuesday, beating analyst expectations on both the top and bottom lines. Despite headwinds from a strategic product exit, management struck an optimistic tone on the company’s core growth areas and raised its full-year organic revenue outlook.
Revenue Misses on a Reported Basis, But Beats on Underlying Measures
For the three months ended March 31, 2026, CONMED generated sales of $317.0 million. While this represents a 1.3% decline year-over-year due to the exit of certain gastroenterology (GI) products, the result came in slightly above the analyst consensus estimate of $316.7 million.
The headline sales decline is largely an accounting effect. Revenue was dragged down by a $15.5 million reduction from the divested GI portfolio. Excluding this impact, management highlighted strong underlying organic growth. International revenue was a bright spot, climbing 4.7% year-over-year as reported (1.0% in constant currency), while domestic revenue fell 5.8% due to the GI product exit.
Profitability Beats Estimates on Strong Margin Execution
Reported GAAP diluted earnings per share were $0.45, a significant jump from $0.19 in the same quarter last year. However, the more closely watched adjusted diluted net earnings per share (EPS) came in at $0.89, comfortably above the analyst estimate of $0.84.
The improvement in profitability is notable. Gross margin expanded markedly to 57.9% of sales compared to 55.3% in the year-ago period, driven by a favorable product mix shift away from lower-margin GI products and toward higher-margin surgical specialties.
Market Reaction and Forward Outlook
The market’s response has been muted in the immediate aftermath. The stock is flat in after-market trading, and it has seen a mixed performance in recent weeks with a 1.7% gain over the last month but a decline of roughly 6.6% over the past week.
The modest price reaction may be tied to the company’s full-year earnings guidance. While management raised its organic revenue growth forecast on a constant currency basis to approximately 5.0% to 6.5% (up from 4.5% to 6.0%), the full-year adjusted EPS guidance range of $4.30 to $4.45 was left unchanged. This guidance is generally in line with the analyst consensus of $4.44, but the midpoint of the range falls slightly below the average estimate. Management noted that stronger underlying operating performance is being largely offset by higher anticipated interest expense from a planned debt refinancing in 2026.
Key points from the press release and financials:
- Reported Revenue: $317.0 million (-1.3% YoY) vs. estimate of $316.7 million.
- Adjusted EPS: $0.89 vs. estimate of $0.84.
- Segment Performance:
- Orthopedic Surgery revenue grew 6.8% YoY as reported.
- General Surgery revenue fell 7.4% YoY as reported, impacted by the GI product exit.
- Capital Products revenue grew 4.6% YoY as reported.
- Margins: Gross profit margin improved to 57.9% of sales, up from 55.3% a year ago. Operating income more than doubled to $25.4 million.
- Full-Year 2026 Guidance:
- Revenue: $1.350 billion to $1.375 billion (raised from $1.345 billion to $1.375 billion).
- Organic Constant Currency Growth: 5.0% to 6.5% (raised from 4.5% to 6.0%).
- Adjusted Diluted EPS: $4.30 to $4.45 (reaffirmed).
Strategic Focus
CEO Patrick J. Beyer underscored the company’s strategy of concentrating resources on its highest-growth areas. “We continue to concentrate our resources and investment on our higher-growth, higher-margin areas: minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair,” he said in the earnings release.
For a deeper dive into historical earnings data and future projections for CONMED, including the upcoming Q2 2026 consensus estimate of $347.4 million in sales and detailed analyst forecasts, visit the dedicated earnings page and forecast page.
View CONMED’s Full Earnings History and Analyst Estimates
See CONMED’s Future Projections and Analyst Ratings
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Please consult with a qualified financial professional before making any investment decisions.